Is CRXTQ or BTI a better dividend investment in 2026?

CRXTQ currently yields 142857.14% with a 5% 5-year dividend growth rate. BTI yields 5.38% with 5% growth. The better choice depends on your goal: CRXTQ offers higher current income.

What is the dividend yield difference between CRXTQ and BTI?

CRXTQ has a forward dividend yield of 142857.14% ($2.00/share annually). BTI yields 5.38% ($3.15/share annually). The yield gap is 142851.76 percentage points.

Home › Compare › CRXTQ vs BTI

CRXTQ vs BTI: Dividend Comparison 2026

CRXTQ yields 142857.14% · BTI yields 5.38%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CRXTQ wins by $1.703105290929614e+28M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CRXTQ

● Live price

142857.14%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$1.703105290929614e+28M

Annual income

$17,007,633,297,048,937,000,000,000,000,000,000.00

Full CRXTQ calculator →

BTI

● Live price

5.38%

Share price

$58.47

Annual div

$3.15

5Y div CAGR

11.3%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$37.7K

Annual income

$2,786.64

Full BTI calculator →

Portfolio growth — CRXTQ vs BTI

📍 CRXTQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CRXTQ	BTI
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CRXTQ + BTI cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CRXTQ pays

BTI pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRXTQ

Annual income on $10K today (after 15% tax)

$12,142,857.14/yr

After 10yr DRIP, annual income (after tax)

$14,456,488,302,491,595,000,000,000,000,000,000.00/yr

BTI

Annual income on $10K today (after 15% tax)

$457.40/yr

After 10yr DRIP, annual income (after tax)

$2,368.64/yr

At 15% tax rate, CRXTQ beats the other by $14,456,488,302,491,595,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRXTQ + BTI for your $10,000?

CRXTQ: 50%BTI: 50%

100% BTI50/50100% CRXTQ

Portfolio after 10yr

$8.51552645464807e+27M

Annual income

$8,503,816,648,524,468,000,000,000,000,000,000.00/yr

Blended yield

99.86%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

CRXTQ

Analyst Ratings

Buy

Hold

Consensus: Hold

BTI

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$40.00

-31.6% upside vs current

Range: $40.00 — $40.00

Altman Z

2.1

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRXTQ buys

BTI buys

No recent congressional trades found for CRXTQ or BTI in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCRXTQBTI

Forward yield	142857.14% ✓	5.38%
Annual dividend / share	$2.00	$3.15 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	11.3% ✓
Portfolio after 10y	$1.703105290929614e+28M	$37.7K ✓
Annual income after 10y	$17,007,633,297,048,937,000,000,000,000,000,000.00 ✓	$2,786.64
Total dividends collected	$1.70295189426983e+28M	$14.3K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Hold	Buy

Year-by-year: CRXTQ vs BTI ($10,000, DRIP)

Year	CRXTQ Portfolio	CRXTQ Income/yr	BTI Portfolio	BTI Income/yr	Gap
1← crossover	$14,296,414	$14,285,714.29	$11,299	$598.92	+$14.29M → CRXTQ
2	$19,102,632,658	$19,087,335,494.95	$12,794	$703.91	+$19102.62M → CRXTQ
3	$23,856,124,353,624	$23,835,684,536,679.88	$14,518	$829.07	+$23856124.34M → CRXTQ
4	$27,845,102,711,212,050	$27,819,576,658,153,670.00	$16,513	$978.64	+$27845102711.20M → CRXTQ
5	$30,376,787,884,694,190,000	$30,346,993,624,793,194,000.00	$18,827	$1,157.84	+$30376787884694.17M → CRXTQ
6	$30,972,831,647,170,750,000,000	$30,940,328,484,134,132,000,000.00	$21,518	$1,373.12	+$30972831647170752.00M → CRXTQ
7	$29,516,720,240,819,920,000,000,000	$29,483,579,310,957,454,000,000,000.00	$24,657	$1,632.46	+$29516720240819920896.00M → CRXTQ
8	$26,290,911,335,300,946,000,000,000,000	$26,259,328,444,643,270,000,000,000,000.00	$28,329	$1,945.74	+$2.6290911335300947e+22M → CRXTQ
9	$21,887,488,081,496,375,000,000,000,000,000	$21,859,356,806,367,600,000,000,000,000,000.00	$32,637	$2,325.33	+$2.1887488081496375e+25M → CRXTQ
10	$17,031,052,909,296,140,000,000,000,000,000,000	$17,007,633,297,048,937,000,000,000,000,000,000.00	$37,708	$2,786.64	+$1.703105290929614e+28M → CRXTQ

CRXTQ vs BTI: Complete Analysis 2026

CRXTQ — Stock

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full CRXTQ Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →

📬

Get this CRXTQ vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRXTQ vs SCHD CRXTQ vs JEPI CRXTQ vs O CRXTQ vs KO CRXTQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.